This study was performed to investigate whether WIN 55,212-2 (WIN), a cannabinoid receptor agonist, could attenuate blood-brain barrier (BBB) disruption in focal cerebral ischemia in rats and whether the CB1 receptor antagonist rimonabant could prevent this attenuation. A total of 0.3 or 1 mg/kg of WIN was injected intravenously before and after permanent middle cerebral artery (MCA) occlusion. Some animals were pretreated with rimonabant 2 mg/kg i.p. before receiving 0.3 mg/kg of WIN. At 1 h after MCA occlusion, BBB permeability was determined by measuring the transfer coefficient (Ki) of 14C-α-aminoisobutyric acid and the volume of dextran distribution. With MCA occlusion, Ki increased in the ischemic cortex (IC) in all of the experimental groups. However, the Ki of the IC of the WIN 0.3 and 1 mg/kg groups was lower (–46 and –42%, respectively, p < 0.05) than that of the control group. With rimonabant pretreatment, the Ki of the IC became higher (+88%, p < 0.05) than with WIN 0.3 mg/kg alone and similar to that of the control rats. The difference in the volume of dextran distribution between the IC and the contralateral cortex was significant in the control but not in the WIN-treated rats. With rimonabant pretreatment, however, the difference became significant. Our data demonstrated that WIN could attenuate BBB disruption in focal cerebral ischemia and this attenuation could be prevented with rimonabant. Our data suggest an involvement of CB1 receptors in the regulation of BBB disruption in the early stage of stroke.

Keywords:
Rimonabant, Cannabinoid receptor, WIN 55,212-2, Blood-brain barrier, Focal cerebral ischemia
1.
Albayrak S, Zhao Q, Siesjo BK, Smith ML: Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury. Acta Neuropathol 1997;94:158–163.
2.
Chi OZ, Hunter C, Liu X, Chi Y, Weiss HR: Effects of GABAA receptor blockade on regional cerebral blood flow and blood-brain barrier disruption in focal cerebral ischemia. J Neurol Sci 2011;301:66–70.
3.
Koenig H, Trout JJ, Goldstone AD, Lu CY: Capillary NMDA receptors regulate blood-brain barrier function and breakdown. Brain Res 1992;588:297–303.
4.
Chi OZ, Wei HM, Sinha AK, Weiss HR: Effects of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia. Pharmacology 1994;48:367–373.
5.
Mayhan WG, Didion SP: Glutamate-induced disruption of the blood-brain barrier in rats: role of nitric oxide. Stroke 1996;27:965–969, discussion 970.
6.
Nag S: Protective effect of flunarizine on blood-brain barrier permeability alterations in acutely hypertensive rats. Stroke 1991;22:1265–1269.
7.
Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47:345–358.
8.
Mackie K: Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006;46:101–122.
9.
Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF: Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 2008;152:753–760.
10.
Jin KI, Mao XO, Goldsmith PC, Greenberg DA: CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000;48:257–261.
11.
Hampson RE, Miller F, Palchik G, Deadwyler SA: Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology 2011;60:944–952.
12.
Li Q, Yan H, Wilson WA, Swartzwelder HS: Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells. Brain Res 2010;1342:127–137.
13.
Mackie K, Lai Y, Westenbroek R, Mitchell R: Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15:6552–6561.
14.
Shen M, Piser TM, Seybold VS, Thayer SA: Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996;16:4322–4334.
15.
Sharp CD, Hines I, Houghton J, Warren A, Jackson IV TH, Jawahar A, Nanda A, Elrod JW, Long A, Chi A, Minagar A, Alexander JS: Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Heart Circ Physiol 2003;285:H2592–H2598.
16.
Palazzo E, Marabese I, de Novellis V, Oliva P, Rossi F, Berrino L, Rossi F, Maione S: Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 2001;40:319–326.
17.
Rizzo V, Ferraro G, Carletti F, Lonobile G, Cannizzaro C, Sardo P: Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Neurosci Lett 2009;462:135–139.
18.
Hillard CJ: Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 2008;14:2347–2361.
19.
Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA: Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002;22:9771–9775.
20.
Gross PM, Blasberg RG, Fenstermacher JD, Patlak CS: The microcirculation of rat circumventricular organs and pituitary gland. Brain Res Bull 1987;18:73–85.
21.
Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413:527–531.
22.
van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K: Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475–6479.
23.
Hansen HH, Azcoitia I, Pons S, Romero J, Garcia-Segura LM, Ramos JA, Hansen HS, Fernandez-Ruiz J: Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 2002;82:154–158.
24.
Biala G, Budzynska B: Rimonabant attenuates sensitization, cross-sensitization, cross-reinstatement of place preference induced by nicotine and ethanol. Pharmacol Rep 2010;62:797–807.
25.
González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J: Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson’s disease. Brain Res 2006;1073–1074:209–219.
26.
Järbe TUC, Gifford RS, Makriyannis A: Antagonism of Δ9-THC induced behavioral effects by rimonabant: time course studies in rats. Eur J Pharmacol 2010;648:133–138.
27.
Varga K, Lake K, Martin BR, Kunos G: Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995;278:279–283.
28.
Blasberg RG, Fenstermacher JD, Patlak CS: Transport of α-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 1983;3:8–32.
29.
Cheer JF, Wassum KM, Wightman RM: Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats. J Neurochem 2006;97:1145–1154.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.